NCT04392232View on ClinicalTrials.gov

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

May 5, 2020

Primary Completion Date

September 21, 2021

Study Completion Date

September 21, 2021

Conditions
CoronavirusCOVID-19Convalescent Plasma
Interventions
DRUG

Convalescent Plasma

"• Investigational Product~o COVID-19 convalescent plasma will be obtained from an FDA-registered blood establishment (Hoxworth) that follows donor eligibility criteria and donor qualifications as outlined in section III.C.I of the Investigational COVID-19 Convalescent Plasma Guidance for Industry."

Trial Locations (2)

45220

Good Samaritan Hospital, Cincinnati

45242

Bethesda North Hospital, Cincinnati

All Listed Sponsors
lead

TriHealth Inc.

OTHER

NCT04392232 - A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection | Biotech Hunter | Biotech Hunter